Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum
- PMID: 20547801
- PMCID: PMC2935001
- DOI: 10.1128/AAC.00183-10
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum
Abstract
We have analyzed the profiles of 23 of Plasmodium falciparum strains for their in vitro chemosusceptibilities to piperaquine (PPQ), dihydroartemisinin (DHA), chloroquine, monodesethylamodiaquine, quinine, mefloquine, lumefantrine, atovaquone, pyrimethamine, and doxycycline (DOX) in association with polymorphisms in genes involved in quinoline resistance (Plasmodium falciparum crt [pfcrt], pfmdr1, pfmrp, and pfnhe). The 50% inhibitory concentrations (IC(50)s) for PPQ ranged from 29 to 98 nM (geometric mean = 57.8 nM, 95% confidence interval [CI] = 51 to 65) and from 0.4 to 5.8 nM for DHA (geometric mean = 1.8 nM, 95% CI = 1.4 to 2.3). We found a significant positive correlation between the responses to PPQ and DHA (r(2) = 0.17; P = 0.0495) and between the responses to PPQ and DOX (r(2) = 0.41; P = 0.001). We did not find a significant association between the PPQ IC(50) (0.0525 < P < 0.9247) or the DHA IC(50) (0.0138 < P < 0.9018) and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe-1 genes. There was an absence of cross-resistance with quinolines, and the IC(50)s for PPQ and DHA were found to be unrelated to mutations in the pfcrt, pfmdr1, pfmrp, and pfnhe-1 transport protein genes, which are involved in quinoline antimalarial drug resistance. These results confirm the interest in and the efficacy of the combination of PPQ and DHA for areas in which parasites are resistant to chloroquine or other quinolines.
References
-
- Arinaitwe, E., T. G. Sandison, H. Wanzira, A. Kahuru, J. Homsy, J. Kalamya, M. R. Kamya, N. Vora, B. Greenhouse, P. J. Rosenthal, J. Tappero, and G. Dorsey. 2009. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin. Infect. Dis. 49:1629-1637. - PubMed
-
- Ashley, E. A., K. M. Lwin, R. Mcgready, W. H. Simon, L. Phaiphun, S. Proux, N. Wangseang, W. Taylor, K. Stepniewska, W. Nawamaneerat, K. L. Thwai, M. Barends, W. Leowattana, P. Olliaro, P. Singhasivanon, N. J. White, and F. Nosten. 2006. An open label randomized comparison of mefloquine-artesunate as separate tablets versus a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Trop. Med. Int. Health 11:1653-1660. - PubMed
-
- Bassat, Q., M. Mulenga, H. Tinto, P. Piola, S. Borrmann, C. Menendez, M. Nambozi, I. Valea, C. Nabasumba, P. Sasi, A. Bacchieri, M. Corsi, D. Ubben, A. Talisuna, and U. D'Alessandro. 2009. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomized, non-inferiority trial. PLoS One 4:7871. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
